Landiolol Shows Effective HR Control Across SVA Subtypes, With Minimal Impact on BP

Background: Landiolol hydrochloride is an ultrashort-acting, highly selective β1-blocker used for rapid control of tachyarrhythmias, particularly atrial fibrillation (AF) and atrial flutter. Although it is widely used in Japan, real-world European data on its use have been limited. Objective: To characterize real-world usage patterns of landiolol in patients with supraventricular arrhythmias (SVA), and to evaluate its effectiveness in heart rate (HR) control, safety profile, patient characteristics, hospital stay duration, and major adverse cardiac outcomes (MACEs) up to 6 months. Design: Prospective, multicenter, observational phase IV study conducted across 8 European countries. Participants: Adult patients receiving IV landiolol for SVA. Methods: Treatment decisions followed routine clinical practice without protocol-driven interventions. Of 450 patients enrolled, 449 were analyzed. Data collection was both retrospective and prospective. Primary end points assessed dosing patterns more...